[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20082460L - Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer - Google Patents

Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer

Info

Publication number
NO20082460L
NO20082460L NO20082460A NO20082460A NO20082460L NO 20082460 L NO20082460 L NO 20082460L NO 20082460 A NO20082460 A NO 20082460A NO 20082460 A NO20082460 A NO 20082460A NO 20082460 L NO20082460 L NO 20082460L
Authority
NO
Norway
Prior art keywords
methods
sustained release
dosage forms
oral dosage
release oral
Prior art date
Application number
NO20082460A
Other languages
English (en)
Inventor
Evangeline G Cruz
Nipun Davar
Gemma Casadevall
Jayne Hastedt
Gaytri Sathyan
Linda Pors
Original Assignee
Alza Corp Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37232345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082460(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp Usa filed Critical Alza Corp Usa
Publication of NO20082460L publication Critical patent/NO20082460L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Beskrevet er fremgangsmåter for vedvarende frigivelsesadministrasjon av opioider, som inkluderer, men er ikke begrenset til, hydromorfon og oksykodon, som fremviser forbedrede egenskaper med hensyn til samtidig inntak med vandig alkohol.
NO20082460A 2005-10-31 2008-05-30 Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer NO20082460L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US80201706P 2006-05-18 2006-05-18
US83704906P 2006-08-11 2006-08-11
PCT/US2006/042687 WO2007053698A2 (en) 2005-10-31 2006-10-31 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Publications (1)

Publication Number Publication Date
NO20082460L true NO20082460L (no) 2008-07-30

Family

ID=37232345

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20064997A NO20064997L (no) 2005-10-31 2006-10-31 Fremgangsmate for redusering av alkoholindusert doseuttomming for opioide orale doseringsformer med langvarig frigivning
NO20082460A NO20082460L (no) 2005-10-31 2008-05-30 Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20064997A NO20064997L (no) 2005-10-31 2006-10-31 Fremgangsmate for redusering av alkoholindusert doseuttomming for opioide orale doseringsformer med langvarig frigivning

Country Status (24)

Country Link
US (1) US20090221621A1 (no)
EP (1) EP1951232B1 (no)
JP (1) JP5315055B2 (no)
KR (1) KR101365031B1 (no)
CN (1) CN103800300A (no)
AT (1) AT10511U1 (no)
AU (1) AU2006308718C8 (no)
BE (1) BE1017786A3 (no)
BG (1) BG1145U1 (no)
CZ (1) CZ17801U1 (no)
DE (1) DE202006014131U1 (no)
DK (2) DK200600272U4 (no)
ES (2) ES1064414Y (no)
FI (1) FI7512U1 (no)
FR (1) FR2892634B3 (no)
HK (2) HK1106451A1 (no)
HU (1) HUP0600816A2 (no)
IE (1) IES20060793A2 (no)
NL (1) NL1032774C1 (no)
NO (2) NO20064997L (no)
PL (2) PL116330U1 (no)
PT (2) PT1951232E (no)
SI (1) SI1951232T1 (no)
WO (1) WO2007053698A2 (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320309B2 (en) 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CN101801979A (zh) 2007-03-29 2010-08-11 普罗热尼奇制药公司 (r)-n-溴化甲基纳曲酮的晶体形式及其用途
CA2865661C (en) 2007-03-29 2016-05-17 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MX336789B (es) * 2007-08-13 2016-02-02 Inspirion Delivery Technologies Llc Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion.
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
BRPI0908114A2 (pt) * 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd tabuleta oral de liberação controlada
JP5674641B2 (ja) 2008-05-09 2015-02-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 噴霧凝固工程の適用下での中間粉末製剤および最終固体剤形の製造方法
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2393487B1 (en) 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
ES2624719T3 (es) * 2009-03-18 2017-07-17 Evonik Röhm Gmbh Composición farmacéutica de liberación controlada con resistencia contra la influencia del etanol empleando un recubrimiento que comprende polímeros de vinilo neutros y excipientes
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US20120207825A1 (en) 2009-09-17 2012-08-16 Sunilendu Bhushan Roy Pharmaceutical compositions for reducing alcohol-induced dose dumping
AU2011219452B2 (en) * 2010-02-24 2014-05-29 Zoetis Llc Veterinary compositions
WO2011112709A1 (en) 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
CA2864738C (en) 2012-04-18 2017-07-18 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EP2893928B1 (en) * 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
US9301918B2 (en) 2013-03-15 2016-04-05 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
CA2985546A1 (en) * 2015-05-13 2016-11-17 4P-Pharma Stimulant abuse-deterrent compositions
WO2016193034A1 (en) * 2015-06-05 2016-12-08 Evonik Röhm Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
WO2020106735A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
EP4255495A1 (en) 2020-12-03 2023-10-11 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2707154A (en) * 1952-06-09 1955-04-26 Monsanto Chemicals Antioxidants and compositions containing same
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (no) 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
CH508415A (de) * 1967-10-27 1971-06-15 Hoffmann La Roche Antioxydative Mischung und deren Verwendung
US3573936A (en) * 1967-12-15 1971-04-06 Rayonier Inc Plicatic acid and thiodipropionic acid as antioxidants for use in animal fats and vegetable oils
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4038434A (en) 1976-03-12 1977-07-26 Howard Hall & Company Antioxidant stabilized edible compositions
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4186465A (en) * 1978-03-28 1980-02-05 Manning Jim L Safety lock
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
IN159370B (no) * 1982-01-15 1987-05-09 Ciba Geigy Ag
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4663148A (en) 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4681853A (en) * 1985-10-23 1987-07-21 Hardy Kenneth J Perfusion slit chamber for filter-bound sample analyses
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
DE669128T1 (de) * 1992-11-17 1996-03-14 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
SI0729357T1 (en) 1993-11-19 2005-06-30 Janssen Pharmaceutica N.V. Microencapsulated 1,2-benzazoles
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
AU3909597A (en) 1996-08-16 1998-03-06 Alza Corporation Dosage form for providing ascending dose of drug
CN1182839C (zh) 1996-11-25 2005-01-05 阿尔萨公司 递增剂量的剂型
JP3739410B2 (ja) * 1997-07-02 2006-01-25 ユーロ−セルティーク エス．エイ． 安定化された徐放性トラマドール製剤
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
AU4319799A (en) 1998-06-03 1999-12-20 Alza Corporation Methods and devices for providing prolonged drug therapy
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
DK1140012T3 (da) 1998-12-17 2004-07-12 Alza Corp Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
ATE419830T1 (de) * 2002-04-29 2009-01-15 Alza Corp Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon

Also Published As

Publication number Publication date
JP2009513717A (ja) 2009-04-02
BG1145U1 (bg) 2009-02-27
EP1951232A2 (en) 2008-08-06
WO2007053698A2 (en) 2007-05-10
CN103800300A (zh) 2014-05-21
ES1064414Y (es) 2007-06-16
NL1032774C1 (nl) 2007-05-02
NO20064997L (no) 2007-05-02
PT1951232E (pt) 2013-05-13
AU2006308718A1 (en) 2007-05-10
AU2006308718B2 (en) 2013-01-10
KR101365031B1 (ko) 2014-02-21
FR2892634B3 (fr) 2007-09-14
AU2006308718C1 (en) 2015-10-08
ES2402666T3 (es) 2013-05-07
EP1951232A4 (en) 2009-03-11
AU2006308718C8 (en) 2015-12-24
FI7512U1 (fi) 2007-05-25
US20090221621A1 (en) 2009-09-03
DK1951232T3 (da) 2013-05-06
AT10511U1 (de) 2009-05-15
FR2892634A3 (fr) 2007-05-04
ES1064414U (es) 2007-03-16
HU0600816D0 (en) 2006-12-28
HUP0600816A2 (en) 2008-05-28
IES20060793A2 (en) 2007-05-30
EP1951232B1 (en) 2013-04-03
HK1115070A1 (en) 2008-11-21
HK1106451A1 (en) 2008-03-14
SI1951232T1 (sl) 2013-06-28
DK200600272U4 (da) 2008-06-13
WO2007053698A3 (en) 2007-06-28
KR20080064198A (ko) 2008-07-08
CZ17801U1 (cs) 2007-09-03
BE1017786A3 (de) 2009-07-07
PL1951232T3 (pl) 2013-09-30
DK200600272U1 (da) 2007-02-23
FIU20060451U0 (fi) 2006-10-30
PL116330U1 (en) 2007-04-02
PT103597A (pt) 2007-05-31
JP5315055B2 (ja) 2013-10-16
DE202006014131U1 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
NO20082460L (no) Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer
DK2292229T3 (da) Manipulationsmodstandsdygtige orale, farmaceutiske doseringsformer indeholdende et opioidanalgetikum
ATE474564T1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
CY1109407T1 (el) Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη
NO20090628L (no) Pyridizinon derivativater
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MX2009003771A (es) Formulaciones robustas de liberacion sostenida.
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
CY1119328T1 (el) Αναστολεας ανοχης σε αναλγητικα
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
EA200870182A1 (ru) Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов
DK1865931T3 (da) Transdermal plaster
NO20063233L (no) Fremgangsmate for redusering av alkoholindusert doseuttomming for opioide orale doseringsformer med langvarig frigivning
EP1849460A3 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
SG170037A1 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
CL2008002005A1 (es) Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.
MX2009003770A (es) Formulaciones de oximorfona robustas, de liberacion sostenida y metodos para su uso.
ES2422293T3 (es) Opiopatias

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application